AGI Therapeutics

Dublin, Ireland Founded: 2005 • Age: 21 yrs Acquired By Aravis
Drug products for lung-related conditions are developed by the company.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 9 Brand Intelligence

About AGI Therapeutics

AGI Therapeutics is a company based in Dublin (Ireland) founded in 2005 was acquired by Aravis in January 2012. AGI Therapeutics operates in a competitive market with competitors including aTyr Pharma, ReCode Therapeutics, GEn1E, Enterprise Therapeutics and Ikaria, among others.

  • Headquarter Dublin, Ireland
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    Not available
  • Acquired by
    Aravis

    (Jan 09, 2012)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of AGI Therapeutics

Premium access

Detailed funding history for AGI Therapeutics

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in AGI Therapeutics

AGI Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Aravis.

All
Venture Fund
Investor Description Founded Year Domain Location
Growth capital is provided by Aravis for Swiss high-tech companies.
Locked Locked Locked
Premium access

Investor details for AGI Therapeutics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by AGI Therapeutics

Investments
Premium access

Investment portfolio details for AGI Therapeutics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - AGI Therapeutics

Premium access

Detailed financials for AGI Therapeutics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Agi Therapeutics Comparisons

AGI Therapeutics Primary company
Description
Drug products for lung-related conditions are developed by t...
Location
Dublin, Ireland
Founded Year
2005
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for AGI Therapeutics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of AGI Therapeutics

AGI Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, ReCode Therapeutics, GEn1E, Enterprise Therapeutics and Ikaria, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Protein biologics are developed for treating rare diseases.
Locked Locked Locked
Precision medicines for lung-related diseases are developed.
Locked Locked Locked
Developer of therapeutics for the treatment of inflammatory and rare diseases
Locked Locked Locked
Developer of therapeutic solutions for the treatment of respiratory diseases such as cystic fibrosis
Locked Locked Locked
Therapies for respiratory-related cardiopulmonary disorders are developed.
Locked Locked Locked
Developer of therapeutics for the treatment of respiratory diseases
Premium access

Detailed competitors of AGI Therapeutics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Agi Therapeutics

Premium access

Complete news archive for AGI Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about AGI Therapeutics

AGI Therapeutics was founded in 2005.

AGI Therapeutics is headquartered in Dublin, Ireland.

AGI Therapeutics was founded in 2005 in Dublin, Ireland, as a specialty pharmaceutical company focused on treatments for lung-related conditions. Operations center on developing targeted drug delivery systems, with the lead candidate AGI-350 undergoing preclinical testing for direct lung administration. Data related to AGI-001, s-pindolol, is licensed from external sources. The company went public in 2006 and was later acquired by Aravis, a member of Vidara Therapeutics.

AGI Therapeutics's top competitors include aTyr Pharma, ReCode Therapeutics and Pulmatrix.

AGI Therapeutics has 1 investor. Key investors include Aravis.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available